A prospective, multicenter, randomized, double blind, Phase III study to compare the efficacy and safety of Biosimilar Adalimumab injection of Enzene Biosciences Ltd. with HUMIRAA (adalimumab) injection in subjects with active Ankylosing spondylitis (AS).
Latest Information Update: 30 Nov 2020
At a glance
- Drugs Adalimumab (Primary)
- Indications Ankylosing spondylitis
- Focus Registrational; Therapeutic Use
- Sponsors Alkem Laboratories; Enzene Biosciences
- 30 Nov 2020 New trial record